A new naloxone nasal spray will soon be available.
A new naloxone nasal spray will soon be available.
Identifying and combating a multifaceted problem, including proven and developing strategies.
A total of 14 different reports examine workers’ comp system performance across 17 states from 2017-2022.
While bureaucratic wheels may take time, marijuana will become a Schedule III drug soon.
Healthe’s VP of Clinical Services, Silvia Sacalis, will co-present this educational session at PRIMA 2024.
Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.
As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.
Visit Healthe at RISKWORLD® 2024 at Booth #1833 for your copy or download a copy now.
If enacted, Senate Bill 2900 would require worker protections from extreme heat and cold.
Different types of cancers are being added to pre-existing presumptions.
Pick up a copy of the new Summer 2024 edition of RxInformer magazine, and learn how Healthe is transforming healthcare.
Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.
As the market grows, it becomes necessary to understand efficacy, costs, and alternatives.
Tenure more than age and other factors had a higher association with cumulative trauma claims.
California, Georgia, New York, Oklahoma, and Pennsylvania could start a national trend.
Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
Amanda Waltemath, Director of Clinical Services joins a panel discussion on April 10th, and Tate Rice, Director of Product Management speaks to Risk & Insurance.
While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.
This sixth annual survey report highlights the top challenges and priorities of 500 industry professionals.
The rule clarifies differences between employees and contractors, establishing who is entitled to benefits – including workers’ comp.
States so far include Alaska, Arizona, California, Hawaii, Indiana, Illinois, Massachusetts, Maryland, New Jersey, and Wisconsin.
The AvertD test is intended to be used prior to first exposure to oral opioids in patients considered for a 4-30 day prescription for acute pain.
With many federal agencies in alignment, the ultimate decision rests with the DEA.
The growing demand for this drug has led individuals to search for semaglutide from alternative sources.
Injuries accompanied by mental health disorders can increase claim costs and delay recovery.
Many states passed or proposed changes in 2023, with two states so far working on bills for 2024.
A recent proclamation applies to simple federal possession charges on or before December 22, 2023.
As legislative sessions open, several states have continued to introduce PTSD bills.
Healthe’s VP of Clinical Services, Silvia Sacalis, will co-present at the 20th Annual Workers’ Compensation Insurance ExecuSummit.
Hypersensitivity reactions may start as a rash but can quickly result in injury to internal organs.
As opioid utilization decreases, other pharmacy trends bear watching.
A new WCRI report utilizes data from 68,850 workers from 2017-2021.
Employers reported 2.8 million nonfatal workplace injuries and illnesses in 2022, an increase of 7.5% from 2021.
The order seeks increased transparency from AI companies regarding model operations, safety and privacy standards, and consumer/worker protections.
Healthe expertise is featured in Risk & Insurance magazine, both on larger industry trends, and on evolving drug trends.
The acetaminophen and ibuprofen combination was approved for IV use, and as an adjunct to opioid therapy for the treatment of pain.
A Healthesystems clinical expert tackles questions about Durable Medical Equipment (DME) trends.
Approximately 45.6% of health workers reported feeling burnout often or very often in 2022.
Similar to a Washington law passed earlier this year, employees are not permitted to possess, to be impaired by, or to use cannabis on the job.
The ketamine molecule is not FDA-approved in any formulation for the treatment of psychiatric disorders.
Tate Rice and Silvia Sacalis share their respective expertise on key issues in physical therapy and pharmacy management.
Exuua was approved for major depressive disorder, while two diabetes medications receive generic approvals.
Potential applications, benefits, pitfalls, questions, and the matter of regulation.
After studying 273 blood samples, researchers could detect long COVID with 96% accuracy.
This law also includes lifeguards, and certain employees in the Departments of Fish and Wildlife and Parks and Recreation.
New insights into how economic and demographic changes have influenced the workers’ comp system.
Healthe’s VP of Clinical Services, Silvia Sacalis, will co-present this educational session at Florida PRIMA 2023.
Binge drinking reached a historic high for adults aged 35-50 in 2022.
Clinical research indicates the potential for strong mental health applications.
Enacted as part of the state’s budget bill, this new regulation comes with stipulations and exclusions.
The likelihood of long COVID, claims costs, and claim duration all increased with the severity of acute COVID-19.
These funds will help states and communities respond more quickly, effectively, and equitably to prevent overdose death and injury.
Kristine Kennedy discusses attributes of effective technology for managed care programs, Silvia Sacalis examines post-opioid epidemic medical trends, and Sandy Shtab speaks on marijuana.
As other Pfizer plants shift gears to make up for this damage, overall drug manufacturing may slow in some areas.
Helpful tips for addressing injured worker unfamiliarity with workers’ comp.
According to JAMA, only 22% of OUD patients received medication-assisted therapy.
The national trend continues, in this case with qualifying events and the inclusion of 911 dispatchers.
RiVive will soon be available without a prescription for the treatment of known or suspected opioid overdose.
Stop by our educational session or visit our booth for the latest issue of RxInformer magazine.
These guidelines advise researchers on study design and other considerations as they develop medications that contain psychedelics.
